PAD-Focused Medtechs Eye Golden Period In Growing Silver Market

Improving the patient’s QoL and preventing disease progression, and with it the threat of critical limb ischemia and amputation, dominate peripheral artery disease management, but emerging technologies and the aging population are set to boost a percutaneous transluminal angioplasty market that is already worth $730 million in the US alone.

Demographic changes are one of the key growth factors driving the market for peripheral vascular interventions and diagnostics for peripheral artery disease (PAD). Other factors include new technological developments, such as drug-eluting balloons, which are improving clinical success rates and expanding the number of patients who can be treated.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo